Harley-Davidson, Inc.

Harley-Davidson, Inc. (NYSE: HOG) is a global leader in heavyweight motorcycles, apparel, parts, and accessories. It sells custom, cruiser, and touring motorcycles and Harley-Davidson parts, accessories, riding gear, clothes, and retail.

Key Highlights

• The company reported a 39.10% rise in motorcycles and related products revenue to USD 4.54 billion in FY21 (ended December 31, 2021) compared to USD 3.26 billion in FY20.
• The company reported a sharp uptick in the bottom line to USD 650.02 million in FY21 from USD 1.30 million in FY20.
• EBITDA and net margins were 15.5% and 12.2%, respectively, higher than the industry median of 8.1% and 5.4%.
• On the other hand, HOG's cash conversion cycle is unusually long, at 175.6 days in FY21, against the industry median of 35.6 days. As of FY21, it has a debt-to-equity ratio of 2.70x, indicating a higher risk to lenders and investors.
• Stock is currently trading above its crucial long-term as well as short-term 50-day and 200-day SMA support levels.
• Stock is currently leaning towards the mid-band of the 52-week range of USD 32.13 to USD 52.06.
• Over the last week and month, HOG's stock price has climbed 15.85% and 8.47%, respectively.

Three-Year Technical Price Chart (as of February 11, 2022; at 3:01 PM ET). Analysis by Kalkine Group

Conclusion: Considering the company's robust growth prospects, solid margins, higher debt, global chip shortage, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 41.43, down 2.70% as of February 11, 2022, at 3:01 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

 Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical firm specializing in developing pharmacological therapy for chronic liver illnesses. CRV431, a cyclophilin inhibitor, is being developed by the company to help treat these numerous complicated diseases.

Key Highlights:

• The company has not yet commenced its core commercial operations.
• Net loss for Q3FY21 increased to USD 9.27 million from USD 6.24 million reported in Q3FY20, attributable to high operating expenditure.
• On January 26, 2022, HEPA revealed the favorable results of a nonclinical research study indicating that when rencofilstat (CRV431) was paired with an anti-PD1 antibody, an immune checkpoint inhibitor (ICI), it synergistically suppressed liver tumor development and extended mice survival.
• The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, indicating a bearish trend.
• It is leaning towards the lower-band of the 52-week range of USD 0.86 to USD 3.18.
• The stock price has fallen 35.85% and 64.08% in the past nine and twelve months.

Three-Year Technical Price Chart (as of February 11, 2022; 3:05 PM ET). Analysis by Kalkine Group

Conclusion: Considering the company's significant losses, positive results from clinical studies, anticipated growth, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 1.02, down 4.67% as of February 11, 2022, at 3:05 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

 Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.